American Association for Cancer Research Annual Meeting (AACR)

Adjuvant durvalumab combined with different monoclonal antibodies led to enriched major pathologic responses in early-stage non–small cell lung cancer.

Patients with solid malignancies may benefit from treatment with next-generation PARP inhibitor AZD5305, according to findings from the phase 1/2a PETRA study.

Antitumor activity was noted for patients with recurrent or metastatic head and neck cancer who were treated with pepinemab plus pembrolizumab.

Patients with resectable gastric and gastroesophageal junction adenocarcinoma experienced good pathologic complete response with standard of care chemotherapy and perioperative/adjuvant pembrolizumab.

Those with inflamed T cell or YAP1–positive extensive-stage small cell lung cancer were likely to gain an improvement in overall survival following treatment with durvalumab and chemotherapy vs those with other overexpressed biomarkers.

Genetic determinants of PSA proved to robustly predict prostate cancer diagnoses and improve the detection of aggressive disease; however, larger and more diverse studies are still required.

Results of CheckMate 649 trial show consistently improved outcomes across advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma when nivolumab is administered in combination with chemotherapy.

The CAR T-cell product BNT211 when used with or without a CAR T cell–amplifying RNA vaccine produced considerable responses and safety in patients with CLDN6-positive advanced solid tumors.

Acceptable efficacy and safety were elicited in patients with advanced solid tumors and high tumor mutational burden detectable in both blood and tissue samples with nivolumab/ipilimumab therapy.

A significant proportion of patients with nonclonal ductal carcinoma in situ were found to have recurrence that was not genetically linked to the primary tumor.

Children and young adults with H3K27M-positive diffuse intrinsic pontine gliomas and spinal diffuse midline gliomas saw a clinical benefit when treated with GD2-directed chimeric antigen receptor T cell therapy.

Updated data from the phase 1/2 CodeBreaK 100 trial of sotorasib provide the longest follow-up of a KRAS G12C inhibitor in non–small cell lung cancer.

Data regarding different dosing strategies of elimusertib for advanced solid tumors with ATM alterations and other DNA damage repair gene defects display early efficacy of the therapy.

Biomarker analysis and studies of pharmacokinetics, pharmacodynamics, and T-cell composition show certain T-cell characteristics are linked with outcomes and toxicity with axicabtagene ciloleucel in large B-cell lymphoma.

Investigators of a phase 1/2 trial observed positive response outcomes with expanded natural killer cells plus AMF13 in patients with heavily pretreated lymphoma.

Data presented from the 4-year follow-up to the phase 3 KEYNOTE-042 trial display continuous survival benefit of pembrolizumab vs chemotherapy in Chinese patients with untreated non–small cell lung cancer.

Early findings from the phase 1/2a TEM-GBM study presented at the 2022 AACR Annual Meeting displayed potential of temferon to affect the tumor microenvironment of glioblastoma.

Data from a phase 1/2 trial examining nivolumab plus a PD-L1/IDO peptide vaccine indicates early activity in patients with metastatic melanoma, according to results from the 2022 AACR Annual Meeting.

CancerNetwork® spoke with Cynthia X. Ma, MD, PhD, of Washington University School of Medicine in St. Louis, following the American Association for Cancer Research Annual Meeting 2021 about the benefits of the meeting to clinical trial investigators.

CancerNetwork® spoke with Cynthia X. Ma, MD, PhD, during the American Association for Cancer Research Annual Meeting 2021 about data supporting the potential use of the exemestane/leuprolide acetate plus pembrolizumab combination.

Alessi detailed his research into cancer aneuploidy and its predictive capabilities for treating patients with non–small cell lung cancer.

Holowatyj detailed the benefits of a conference like that of the American Association for Cancer Research Annual Meeting 2021, which presents opportunities for thought leaders to come together.

CancerNetwork® spoke with Sanju Sinha of the National Cancer Institute about the resulting data from his research into sex differences associated with using tumor mutational burden to predict response to PD-1 inhibition.

Holowatyj touched on the need to learn more about the biological factors contributing to disparities in early-onset colorectal cancer and the associated burden of the disease.

CancerNetwork® spoke with Francesco Ravera, MD, PhD, during the American Association for Cancer Research Annual Meeting 2021 to discuss how results of a study aimed at determining pathological complete response in patients with locally advanced breast cancer by cell-free DNA may spare certain patients from needing further biopsies.

CancerNetwork® spoke with Neelam and Sanju Sinha of the National Cancer Institute about their research into sex differences associated with using tumor mutational burden to predict response to PD-1 inhibition.

CancerNetwork® spoke with Francesco Ravera, MD, PhD, during the American Association for Cancer Research Annual Meeting 2021 to discuss results of a study aimed at determining pathological complete response in patients with locally advanced breast cancer by either cell-free DNA assessment or traditional MRI.

Marron spoke about the value that neoantigen vaccines can provide by studying T-cell responses and the characteristics of lymphoid response to antigens.

CancerNetwork® spoke with Francesco Ravera, MD, PhD, during the American Association for Cancer Research Annual Meeting 2021 to discuss a study that looked at cell-free DNA assessment compared with traditional MRI for determining pathological complete response in patients with locally advanced breast cancer.

Kim discussed the need for further CREB inhibitor combinations to target collateral pathways and improve patient outcomes.